J&J's Cordis lays off, merges sales staff

With demand for its Cypher heart stent diminishing, Johnson & Johnson medical device subsidiary Cordis will lay off some sales reps and merge its cardiovascular and endovascular units sales forces into one Cordis Vascular group. The total number of employees affected remains undisclosed.

And while J&J spokeswoman Sandra Pound told Reuters the cuts are J&J's way of adapting to the medical device market, Gabelli & Co. analyst Jeff Jonas had a different take. "This is another step to respond to its sales declines and market-share losses," he told Reuters.

- check out the Reuters article

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.